Coherus COMPLETE™ Payer
Coverage TOOL

UDENYCA^® (pegfilgrastim-cbqv)

Coverage Announcements

As payers make coverage policy changes and announcements regarding UDENYCA^®, you can stay informed by checking the announcements below.

• September 2020
  

  Independent Health Medicare Policies has updated UDENYCA® (pegfilgrastim-cbqv) to be the Preferred Agent with Neulasta® (pegfilgrastim)

• August 2020
  

  Select Health has updated pegfilgrastim-cbqv (UDENYCA^®) to be the Preferred Agent with pegfilgrastim-jmdb (Fulphila^®)

  Read more: Select Health has updated UDENYCA^® (pegfilgrastim-cbqv) to be the Preferred Agent with Fulphila^® (pegfilgrastim-jmdb)
• June 2020
  

  Florida Medicaid has updated pegfilgrastim-cbqv (UDENYCA^®) to be the Preferred Agent

  Read more: Florida Medicaid has updated UDENYCA^® (pegfilgrastim-cbqv) to be the Preferred Agent
• May 2020
  

  Minnesota Medicaid has updated pegfilgrastim-cbqv (UDENYCA^®) to be the Preferred Agent with all other pegfilgrastim biosimilars

  Read more: Minnesota Medicaid has updated UDENYCA^® (pegfilgrastim-cbqv) to be the Preferred Agent with all other pegfilgrastim biosimilars
• April 2020
  

  CVS/Aetna has updated UDENYCA^® to be the Preferred Biosimilar and is co-preferred with Neulasta^® (pegfilgrastim).

  Read More: CVS/Aetna has updated UDENYCA^® to be the Preferred Biosimilar and is co-preferred with Neulasta^®
• March 2020
  

  Short Term Recommendations from NCCN Guidelines^® & ASCO^® Regarding use of Hematopoietic Growth Factors during COVID-19 Pandemic*
  
  Due to COVID-19 pandemic, the short-term recommendations from the NCCN Guidelines^® and ASCO^® have lowered the threshold for the use of myeloid growth factors from those chemotherapy regimens which have a 20% or higher risk of febrile neutropenia to now include those regimens with a risk of 10-20%, which includes all of the intermediate risk chemotherapy regimens.

  Read More: NCCN Guidelines for Hematopoietic Growth Factors: Short-Term Recommendations Specific to Issues with COVID-19 (SARS-CoV-2)
  
  Read More: ASCO COVID-19 Update to Hematopoietic Growth Factors Guidelines
• March 2020
  

  BCBS Vermont has updated pegfilgrastim-cbqv (UDENYCA^®) to be the Preferred Agent with pegfilgrastim-bmez (Ziextenzo^®)

• March 2020
  

  Select Health has updated UDENYCA^® to be the Preferred Agent with Neulasta^® (pegfilgrastim).

  Read More: Select Health has updated UDENYCA^® to be the Preferred Agent with Neulasta^®
• January 2020
  

  Ventegra has updated UDENYCA^® to be the Preferred Pegfilgrastim on their Formulary.

  Read More: Ventegra has updated UDENYCA^® to be the Preferred Pegfilgrastim on their Formulary
• January 2020
  

  Express Scripts has updated UDENYCA^® to be the Preferred Agent with Neulasta^® (pegfilgrastim) in the National & Basic Formulary List.

  Read More: Express Scripts has updated UDENYCA^® to be the Preferred Agent with Neulasta^®
• May 2019
  

  UDENYCA^® has been Added to the TriCare Uniform Formulary.

  Read More: UDENYCA^® has been Added to the Tricare Uniform Formulary
• April 1st, 2019
  

  UDENYCA^® assigned transitional pass-through status April 1, 2019.

  Read More: April 2019 Update of the Hospital OPPS
• April 1st, 2019
  

  UDENYCA^® added to BuyandBill.com.

  Read More: Buyandbill.com UDENYCA^®
• March 2019
  

  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Growth Factors Updated to include pegfilgrastim-cbqv*

  Read More: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Growth Factors Updated to include Pegfilgrastim-cbqv

* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Growth Factors V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July 13, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.